Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:

NCT ID: NCT03274063 Completed - Gout Clinical Trials

Gout Self-Monitoring Aiming to Reach Target

Gout-SMART
Start date: April 5, 2019
Phase: N/A
Study type: Interventional

This study evaluates whether a supported self-management approach to gout is able to achieve target levels of serum urate, and better control of gout flares.

NCT ID: NCT03272425 Completed - Gout Clinical Trials

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Start date: August 14, 2017
Phase: Phase 1
Study type: Interventional

To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic (PK) evaluation of lesinurad and allopurinol in healthy adult subjects.

NCT ID: NCT03211403 Completed - Gout Clinical Trials

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

Start date: July 4, 2017
Phase: Phase 1
Study type: Interventional

This is a single-Center, randomized, double-Blind, placebo-controlled, multiple ascending-dose Phase I trail.

NCT ID: NCT03162341 Completed - Gout Clinical Trials

Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit

GOUT
Start date: August 10, 2017
Phase: N/A
Study type: Interventional

The objective of this research is to evaluate the correlation between DECT and US explorations performed in a routine clinical setting for the measurement of change in tophus size in gout patients after 24 months of treatment.

NCT ID: NCT03131583 Completed - Gout Clinical Trials

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

Start date: February 17, 2017
Phase: Phase 1
Study type: Interventional

The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640, Febuxostat and Colchicine interaction in patients with gout.

NCT ID: NCT03100318 Completed - Clinical trials for Hyperuricemia With or Without Gout

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: April 1, 2017
Phase: Phase 3
Study type: Interventional

FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

NCT ID: NCT03015948 Completed - Gout Clinical Trials

A Single Dose Study of SHR4640 in Healthy Male Volunteers

Start date: September 22, 2016
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose Phase I trial.

NCT ID: NCT03006445 Completed - Clinical trials for Hyperuricemia With or Without Gout

Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and ascending dose regimen.

NCT ID: NCT02959918 Completed - Hyperuricemia Clinical Trials

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and hyperuricemia. Additional participants will be treated with multiple doses ( 5 monthly IV infusions) of pegsiticase (SEL-037) alone. Participants will be monitored for safety endpoints through the 5th treatment cycle plus 30 days .Pharmacokinetic samples will be drawn at pre-determined time points in addition to weekly serum uric acid levels.

NCT ID: NCT02950142 Completed - Obesity Clinical Trials

Evidence-based Laboratory Test Order Sets in Primary Care

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.